布加综合征患者血清差异蛋白分析

Analysis of serum differential proteins in patients with Budd-Chiari syndrome

目的:通过同位素相对标记与绝对定量技术(iTRAQ)鉴定和分析布加综合征(BCS)及对照组血清蛋白表达差异。方法:收集蚌埠医学院第一附属医院首次住院治疗的30例BCS患者与30例下肢静脉曲张患者血清,利用iTRAQ技术检测出具有显著差异表达蛋白质,探究差异蛋白的生物学信息及相关信号通路。应用Omics Bean数据库对差异蛋白进行基于GO的生物学过程(BP)、细胞成分(CC)及分子功能(MF)分类,应用STRING(http://string-db.org/)数据库对蛋白质相互作用网络(PPI)分析。结果:共检测出差异蛋白143种,BCS组有76个蛋白显著升高,有67个蛋白显著降低( P值均<0.05)。参与的主要生物学过程为防御反应、囊泡介导转运、免疫效应过程、补体激活和血液凝集等重要生物学过程( P<0.05)[注:该处 P值是通过Fisher精确检验方法,富集分析的 P值只有矫正值的错误发现率(FDR)]。 结论:运用iTRAQ技术鉴定出BCS组与对照组的差异蛋白,部分蛋白可能成为诊断BCS的特异性血清生物标志物。

Objective To identify and quantitatively analyze serum protein expression in patients with Budd-Chiari syndrome(BCS)and control group by isobaric tags for relative and absolute quantitation(iTRAQ).Methods Serum was collected from 30 patients with BCS and 30 patients with varicose veins of lower limbs,using iTRAQ technology to detect the significant differentially expressed proteins,to explore the differences in protein biological information and related signaling pathway.Results A total of 143 kinds of differentially expressed proteins were detected.76 proteins in the BCS group were significantly increased and 67 proteins were significantly decreased(all P<0.05).The main biological processes involved are defense response,vesicle-mediated transport,immune effect process,complement activation and blood agglutination(all P<0.05).Conclusion ITRAQ technology is used to identify the differential proteins between BCS group and control group,Some proteins may be specific serum biomarkers for the diagnosis of BCS,and these proteins provide new directions for the study of the pathogenesis of BCS.